AlloVir, Inc. (ALVR)

NASDAQ: ALVR · IEX Real-Time Price · USD
6.83
-0.41 (-5.66%)
At close: Dec 9, 2022 4:00 PM
7.17
+0.34 (4.98%)
After-hours: Dec 9, 2022 4:54 PM EST
-5.66%
Market Cap 674.50M
Revenue (ttm) n/a
Net Income (ttm) -188.52M
Shares Out 84.95M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 167,392
Open 7.25
Previous Close 7.24
Day's Range 6.8 - 7.33
52-Week Range 3.17 - 19.08
Beta 0.67
Analysts Buy
Price Target 26.78 (+292.1%)
Earnings Date Nov 4, 2022

About ALVR

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenz... [Read more]

Industry Biotechnology
IPO Date Jul 30, 2020
CEO Scott M. McFarlane
Employees 107
Stock Exchange NASDAQ
Ticker Symbol ALVR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ALVR stock is "Buy." The 12-month stock price forecast is 26.78, which is an increase of 292.09% from the latest price.

Price Target
$26.78
(292.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference

WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p...

3 weeks ago - Business Wire

AlloVir Reports Third Quarter 2022 Financial Results

WALTHAM, Mass.

1 month ago - Business Wire

Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?

The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 259.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana...

3 months ago - Zacks Investment Research

AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will par...

3 months ago - Business Wire

Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect?

The consensus price target hints at a 251.2% upside potential for AlloVir, Inc. (ALVR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

3 months ago - Zacks Investment Research

AlloVir Reports Second Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the second quarter en...

4 months ago - Business Wire

Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know

The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 447% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy...

4 months ago - Zacks Investment Research

AlloVir Announces $126.6 Million Registered Direct Offering

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered into a securities purchase agreement wit...

4 months ago - Business Wire

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of p...

6 months ago - Business Wire

AlloVir Reports First Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter end...

7 months ago - Business Wire

AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

7 months ago - Zacks Investment Research

Why Is AlloVir (ALVR) Stock Up 30% Today?

AlloVir (ALVR) stock is taking off on Wednesday following an update from the U.S. Food and Drug Administration (FDA) on posoleucel. The post Why Is AlloVir (ALVR) Stock Up 30% Today?

7 months ago - InvestorPlace

Why AlloVir Stock Is Surging Today

AlloVir Inc (NASDAQ: ALVR) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its lead in...

7 months ago - Benzinga

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multip...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regen...

7 months ago - Business Wire

AlloVir Appoints Shawn Tomasello to Its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. ...

8 months ago - Business Wire

AlloVir (ALVR) Begins Study to Prevent Six Viral Infections

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

8 months ago - Zacks Investment Research

AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infectio...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the initiation of a Phase 3 registrational study of posoleucel, an...

8 months ago - Business Wire

AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participa...

9 months ago - Business Wire

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, ...

9 months ago - Business Wire

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Ade...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted its lead multi-virus...

11 months ago - Business Wire

AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present a...

11 months ago - Business Wire

AlloVir Announces Departure of Chief Medical Officer Augustin Melian

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially lea...

11 months ago - Business Wire

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 6...

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 ...

11 months ago - Business Wire

AlloVir to Host Virtual Investor Event

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced it will host a virtual investor event on Monday, December 13, 2021, at 8:00 a.m. EST....

1 year ago - Business Wire